Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Prediabetes Market is Projected to Boost at a Moderate Growth Rate by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk, Aphaia Pharma, HighTide Biopharma Pty Ltd, Eli Lilly and Company, Corcept Therapeutics

DelveInsight Logo

News provided by

DelveInsight Business Research, LLP

Jun 19, 2024, 17:31 ET

Share this article

Share toX

Share this article

Share toX

There is a huge unmet need in the prediabetes market for approved therapies since their effective treatment and management can lead to the prevention of diabetes. There are no US FDA-approved drugs available for the treatment of prediabetes. Companies like Novo Nordisk (semaglutide) and Aphaia Pharma (APH-012) are engaged in developing therapies for the treatment of prediabetes.

LAS VEGAS, June 19, 2024 /PRNewswire/ -- DelveInsight's Prediabetes Market Insights report includes a comprehensive understanding of current treatment practices, prediabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Prediabetes Market Report

  • According to DelveInsight's analysis, the market size for prediabetes is expected to grow significantly by 2034.
  • As per DelveIsight assessment, 70.5% of prediabetes cases are found in the 25–44 age group, while 40% and 51% of diabetes cases are found in 25–44 and 45–60 aged individuals, respectively.
  • Leading prediabetes companies such as Novo Nordisk, Aphaia Pharma, HighTide Biopharma Pty Ltd, Eli Lilly and Company, Corcept Therapeutics, and others are developing novel prediabetes drugs that can be available in the prediabetes market in the coming years. 
  • The promising prediabetes therapies in the pipeline include Semaglutide, APH-012, HTD1801, Tirzepatide, and Relacorilant, among others.
  • In May 2024, Novo Nordisk presented the Phase III trial (STEP 10) results of semaglutide in subjects with obesity and prediabetes at the 31st European Congress on Obesity (ECO). The results demonstrated that semaglutide 2.4 mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes.

Discover which therapies are expected to grab the major prediabetes market share @ Prediabetes Market Report

Prediabetes Overview

Prediabetes is a condition characterized by blood sugar levels that are higher than normal but not yet high enough to be diagnosed as type 2 diabetes. It serves as a critical warning sign and a window of opportunity for individuals to take steps to prevent the progression to diabetes. The primary causes of prediabetes include insulin resistance, where the body's cells do not respond effectively to insulin, and the pancreas's inability to produce enough insulin to manage blood sugar levels. Risk factors for developing prediabetes include being overweight, having a sedentary lifestyle, poor dietary habits, a family history of diabetes, and certain health conditions like hypertension and polycystic ovary syndrome (PCOS).

Symptoms of prediabetes are often subtle or non-existent, making it difficult for individuals to recognize the condition. However, some people may experience signs such as increased thirst, frequent urination, fatigue, and blurred vision. Despite the lack of pronounced symptoms, it is crucial to diagnose prediabetes early through appropriate testing. Diagnosis typically involves a fasting plasma glucose test, an oral glucose tolerance test, or an HbA1c test, which measures average blood sugar levels over the past two to three months. Detecting prediabetes early allows for timely lifestyle interventions, including weight loss, increased physical activity, and dietary changes, which can significantly reduce the risk of progressing to type 2 diabetes and improve overall health.

Prediabetes Epidemiology Segmentation

The prediabetes epidemiology section provides insights into the historical and current prediabetes patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The prediabetes market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalent Cases of Prediabetes
  • Total Diagnosed Prevalent Cases of Prediabetes
  • Age-specific Cases of Prediabetes 
  • Gender-specific Cases of Prediabetes
  • Treated Cases of Prediabetes 

Prediabetes Treatment Market 

In addition to adopting a healthy lifestyle, individuals with prediabetes may benefit from various medications aimed at improving insulin function and reducing Impaired Glucose Tolerance (IGT), thereby hindering the progression to type 2 diabetes. Currently, there are no specific treatments for prediabetes; however, medications approved for T2D treatment, such as metformin, thiazolidinediones, GLP-1 analogs, DPP-IV inhibitors, and alpha-glucosidase inhibitors, are commonly utilized.

Metformin functions as an antihyperglycemic agent, enhancing glucose tolerance in individuals with prediabetes or type 2 diabetes by reducing both baseline and after-meal blood sugar levels. It's occasionally prescribed off-label. Metformin achieves this by reducing liver glucose production, intestinal glucose absorption, and by enhancing insulin sensitivity, promoting the uptake and utilization of glucose in peripheral tissues. Another class of medications used for managing these conditions includes orally consumed GLP-1 analogs, which provoke a two- to three-fold increase in plasma insulin response compared to intravenous glucose-induced hyperglycemia. Commonly prescribed GLP-1 receptor agonists such as liraglutide and exenatide are often recommended for individuals with elevated insulin levels (insulin resistance) or those on the brink of developing diabetes.

Subsequently, DPP-IV inhibitors like vildagliptin act by binding covalently to the catalytic site of DPP-4, resulting in prolonged enzyme inhibition. Lastly, alpha-glucosidase inhibitors, known colloquially as starch blockers, are antidiabetic agents that assist in lowering blood glucose levels after meals. Unlike many other diabetes medications, they do not directly impact insulin secretion or sensitivity. Instead, they work by slowing down the breakdown of carbohydrates present in starchy foods. Commonly prescribed alpha-glucosidase inhibitors for managing prediabetes and T2D include acarbose, miglitol, voglibose, among others.

To know more about prediabetes treatment guidelines, visit @ Prediabetes Management 

Prediabetes Pipeline Therapies and Key Companies

The pipeline of prediabetes is not so robust and lacks essential key players. Some of the emerging therapies include semaglutide (Novo Nordisk), APH-012 (Aphaia Pharma), and others.

Novo Nordisk is exploring the effects of a 2.4 mg subcutaneous injection of semaglutide in individuals with obesity and prediabetes. This compound functions as a GLP-1 receptor agonist, operating through various mechanisms such as increasing insulin secretion in response to glucose levels, inhibiting glucagon release, and reducing hepatic gluconeogenesis. These actions lead to a decrease in both fasting and postprandial glucose levels.

In May 2024, Novo Nordisk released findings from the Phase III trial (STEP 10) investigating semaglutide in individuals with obesity and prediabetes. The trial revealed that semaglutide 2.4 mg outperformed the placebo in reducing body weight and returning subjects to normal blood sugar levels, while also showing enhancements in cardiometabolic risk factors.

Aphaia Pharma is currently assessing APH-012 in a Phase II trial to determine its effectiveness in enhancing glucose tolerance among individuals with prediabetes who exhibit abnormal results in the Oral Glucose Tolerance Test (OGTT) after six weeks of receiving APH-012.

Apart from these the other therapies in the pipeline for prediabetes treatment include

  • HTD1801: HighTide Biopharma Pty Ltd
  • Tirzepatide: Eli Lilly and Company
  • Relacorilant: Corcept Therapeutics

The anticipated launch of these emerging therapies for prediabetes are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the prediabetes market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about prediabetes drugs in development @ Prediabetes Clinical Trials 

Prediabetes Market Dynamics

The dynamics of the prediabetes market are expected to change in the coming years. Increased public awareness, improved access to health services, and rising obesity rates act as market drivers, while T2D drugs, effective in treating prediabetes, highlight an unmet need, as there is no approved treatment for prediabetes, creating an opportunity for new players and opening a platform for new therapies to boost the market of the indication.

Furthermore, potential therapies are being investigated for the treatment of prediabetes, and it is safe to predict that the treatment space will significantly impact the prediabetes market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the prediabetes market in the 7MM.

However several factors may impede the growth of the prediabetes market. Although awareness has improved from before, many patients are still unaware that they have this condition, and lack of a uniform classification/diagnostic criteria often leads to confusion and misdiagnosis, potentially affecting the demand for therapeutics as the disease could be controlled by a change in lifestyle; furthermore, off-label usage might hamper the uptake of novel therapies.

Moreover, prediabetes treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the prediabetes market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the prediabetes market growth.

Prediabetes Market Report Metrics

Details

Study Period

2020–2034

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Prediabetes Companies

Novo Nordisk, Aphaia Pharma, HighTide Biopharma Pty Ltd, Eli Lilly and Company, Corcept Therapeutics, and others

Key Pipeline Prediabetes Therapies

Semaglutide, APH-012, HTD1801, Tirzepatide, Relacorilant, and others

Scope of the Prediabetes Market Report

  • Therapeutic Assessment: Prediabetes current marketed and emerging therapies
  • Prediabetes Market Dynamics: Key Market Forecast Assumptions of Emerging Prediabetes Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Prediabetes Market Access and Reimbursement

Download the report to understand which factors are driving prediabetes market trends @ Prediabetes Market Trends

Table of Contents

1.

Prediabetes Key Insights

2.

Prediabetes Report Introduction

3.

Prediabetes Overview at a Glance

4.

Prediabetes Executive Summary

5

Prediabetes Key Events

6

Epidemiology and Market Forecast Methodology

6.

Disease Background and Overview

7.

Prediabetes Treatment and Management

8.

Prediabetes Guidelines

9.

Prediabetes Epidemiology and Patient Population

10.

Patient Journey

11.

Key Endpoints in Prediabetes 

12.

Prediabetes Marketed Drugs

13.

Prediabetes Emerging Drugs

14.

7MM Prediabetes Market Analysis

15.

Market Access and Reimbursement

16.

KOL Views

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Prediabetes Pipeline

Prediabetes Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prediabetes companies, including Resverlogix Corporation, Boston Therapeutics, vTv Therapeutics, Valbiotis, BioTeSys, SynDevRx, Caelus Health, NanoPrecision Medical, among others.

Diabetes Market

Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A,  ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., among others.

Type 1 Diabetes Market

Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Landos Biopharma, Zealand Pharma,  Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,  SQZ Biotech, Enthera, among others.

Type 2 Diabetes Market

Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur  
[email protected]
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Graves' Orbitopathy Market Insights report includes a comprehensive understanding of current treatment practices, Graves' orbitopathy...

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

DelveInsight's CXCR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.